Why Zai Lab Limited’s (ZLAB) Stock Is Down 5.92%
As of Tuesday, October 13, Zai Lab Limited’s ZLAB share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Commentary & Analysis
Why Zai Lab Limited’s (ZLAB) Stock Is Down 5.25%
As of Thursday, October 08, Zai Lab Limited’s ZLAB share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zai Lab Limited’s (ZLAB) Stock Is Down 5.30%
As of Thursday, September 24, Zai Lab Limited’s ZLAB share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zai Lab Limited’s (ZLAB) Stock Is Up 8.30%
As of Wednesday, September 02, Zai Lab Limited’s ZLAB share price has surged by 8.30%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, Xencor, Inc. or Zai Lab Limited Stock?
Learn more about whether Xencor, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | ZLAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,760.6 | $237.5 | 59% |
|
| Shares Out (Mil) | 111.7 | 53.9 | 64% |
|
| Institutional Ownership | 96.6% | 93.1% | 70% |
|
| Float (Mil) | 97.1 | 41.4 | 60% |
|
| Beta | 0.78 | 0.95 | 46% |
|
| Avg Daily Volume (000s) | 770 | 628 | 65% |
|
| Price Change (52-week) |
(24.8%) | 49.0% | 33% |
|
| Growth | ZLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.5% | 12.4% | 97% |
|
| Net Income (5yr) | 8.2% | (10.2%) | 52% |
|
| EPS (5yr) | 14.3% | 15.7% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 10 | 10 | |
| Current EPS | ($0.564) | ($2.196) | ($2.110) | |
| Month Ago EPS | ($0.054) | ($0.775) | ($0.542) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.051) | ($0.210) | ($0.202) | |
| Year/Year Chg | 24.0% | 37.0% | (23.9%) | |
| Financials | ZLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $450 | $37 | 40% |
|
| Net Income (TTM) (Mil) | ($188) | ($44) | 7% |
|
| EPS (TTM) | ($1.698) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($133) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($125) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $2,508 | $174 | 52% |
|
| Valuation | ZLAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.55 | 2.27 | 78% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZLAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 3.8% | 66.9% | 6% |
|
| Net Margin | (41.9%) | (75.3%) | 13% |
|
| ROA | (16.8%) | (47.7%) | 21% |
|
| ROE | (26.9%) | (55.0%) | 21% |
|
| Liabilities to Assets | 43.5% | 29.4% | 35% |
|
| F-Score | 4 | 2 | 33% |
|
Zai Lab Limited did not pass any screens on 10/12/2026.
